Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

Antibodies to Detect Coronavirus Disease 2019 (SARS-CoV-2) Proteins

February 2020

Antibodies to Detect Coronavirus Disease 2019 (SARS-CoV-2) Proteins

Coronavirus Antibodies, the first in the market to detect the Coronavirus disease 2019 nucleoprotein (previously nCOVID-19 now SARS-CoV-2)


MILPITAS, Calif. - Feb. 19, 2020 - PRLog -- Coronaviruses are large, non-segmented positive-sense RNA viruses that are known to affect humans, birds and mammals. They are characterized by club-shaped spike-like projections that arise from the virion surface. The viruses are enveloped and spherical in shape with a diameter of 100-160 nm, with genome length of 30 kb. The 5'-terminal of the viral genome encodes a protein that upon cleavage yields several non-structural proteins that are involved in functions such as viral transcription and replication.The 3'-terminal encodes 4 structural proteins, namely, Spike (S), Envelope (E), Membrane (M) and Nucleocapsid (N) that play important roles in the synthesis of viral RNA and viral replication.

Coronaviruses that affect humans are characterized by being zoonotic, which means these viruses are capable of spreading from non-human sources (animals) to humans. Of the 6 known Coronaviruses that infect humans, two of them are known to cause severe diseases with high rates of mortality. They are Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle-East Respiratory Syndrome Coronavirus (MERS-CoV). In December 2019, another novel strain of Coronavirus was discovered by the Chinese scientists that caused severe viral outbreak in Wuhan, China. This virus is not the same as SARS-CoV or MERS-CoV, and has been officially named as by the World Health Organization as SARS-CoV-2. There is very little information available regarding the role of the SARS-CoV-2 proteins in viral pathogenesis and replication. Hence, there are limited antibodies available in the market to detect these proteins.

BioVision is pleased to announce the launch of Coronavirus Antibodies, the first in the market. These antibodies specialize in detecting the Coronavirus disease 2019 nucleoprotein (previously nCOVID-19, now SARS-CoV-2) and have been tested using research techniques such as Western Blot, ELISA and Immunohistochemistry. These antibodies are available in both polyclonal and monoclonal formats and can readily be shipped worldwide.

Figure: Figures: Western blot analysis of lysates using Anti-SARS-CoV-2 antibodies. (A). Monoclonal (A2060-50). (B). Polyclonal (A2061-50).

For more information on this assay kit, visit:

About BioVision:

BioVision, Inc. is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, and more.

« Back